Global pharmaceutical company Eisai has rolled out Aricept Dry Syrup 1%, a new medicine for Alzheimer's disease treatment Aricept (donepezil hydrochloride) in Japan.
The formulation received Japan manufacturing and marketing authorization on 15 February 2013, and has been placed on the country's National Health Insurance (NHI) drug price list on 21 June 2013.
As per the individual patient requirements, Aricept Dry Syrup 1% allows the dosage to be adjusted within the range of approved dosage amounts at the time of administration.
The suspension formulation has a sweetening agent and is anticipated that it will improve drug compliance among patients who dislike or find it difficult to administer existing formulations and decrease the burden in administering the drug.
The dry syrup, which will be used in the treatment of mild to severe Alzheimer's disease, can also be taken with water in the same way as the existing fine granules formulation, for easy swallowing of the medicine.
